Skip to main content
Fig. 9 | BMC Biology

Fig. 9

From: The mitochondrially-localized nucleoside diphosphate kinase D (NME4) is a novel metastasis suppressor

Fig. 9

NME4-related metastasis-suppression and prognosis in human cancer. A Experimental metastasis assay, where different HeLa clones, empty vector (CTR1, CTR2), wild-type (WT1, WT2), and the kinase-dead mutant (KD1, KD2), were injected in the tail vein of nude mice. After 13 weeks, mice were sacrificed, lungs removed, and the number of lung metastases counted. Total number of lung metastases per section is given after pooling both clones of the same condition (CTR, WT, KD). Eighteen mice of each condition CTR, WT, KD were analyzed. *p<0.05 relative to control/empty vector (CTR); ###p<0.001 relative to wild-type (WT). B mRNA levels of NME4 in four different human breast tumor subtypes, TNBC (triple-negative breast cancer), HR-/ERBB2+ (hormone receptors negative, HER2 positive), HR+/ERBB2- (hormone receptors positive, HER2 negative), and HR+/ERBB2+ (hormone receptors positive, HER2 positive) in a cohort of 526 human breast tumor clinical specimens. $$$p<0.001. C–J Kaplan-Meier analysis of overall survival according to NME4 mRNA expression in KM plotter database of invasive breast carcinoma (C), ovarian serous cystadenocarcinoma (D), lung carcinoma (E), pancreatic ductal adenocarcinoma (F), uterine corpus endometrial carcinoma (G), esophageal squamous cell carcinoma (H), pheochromocytoma and paraganglioma (I), and sarcoma (J)

Back to article page